Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antipsychotics and associated risk of out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sertraline in primary care: comments on the PANDA trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Beta-blockers for suspected or diagnosed acute myocardial infarction

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Trial Sequential Analysis is a frequentist method to help researchers control the risks of random errors in meta-analyses (1). Fisher and colleagues used Trial Sequential Analysis on cell therapy for heart diseases (2). The present article discusses the usefulness of Trial Sequential Analysis and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher et al. (2). This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind102
Udgave nummer1
Sider (fra-til)21-24
ISSN0009-9236
DOI
StatusUdgivet - 2017

ID: 49120483